Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome

Oana Albai,1,2 Mirela Frandes,3 Bogdan Timar,2,3 Diana-Loreta Paun,4 Deiana Roman,1 Romulus Timar1,2 1Second Department of Internal Medicine, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 2Department of Diabetes and Metabolic Diseases, “Pius Br...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Albai O, Frandes M, Timar B, Paun DL, Roman D, Timar R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	malignant neoplastic disorders type 2 diabetes mellitus hyperinsulinemia metabolic syndrome insulin resistance Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9c28a5d6427d418f9b51493c810b66ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9c28a5d6427d418f9b51493c810b66ab
record_format	dspace
spelling	oai:doaj.org-article:9c28a5d6427d418f9b51493c810b66ab2021-12-02T13:03:41ZLong‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome1178-7007https://doaj.org/article/9c28a5d6427d418f9b51493c810b66ab2020-04-01T00:00:00Zhttps://www.dovepress.com/longterm-risk-of-malignant-neoplastic-disorders-in-type-2-diabetes-mel-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Oana Albai,1,2 Mirela Frandes,3 Bogdan Timar,2,3 Diana-Loreta Paun,4 Deiana Roman,1 Romulus Timar1,2 1Second Department of Internal Medicine, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 2Department of Diabetes and Metabolic Diseases, “Pius Brinzeu” Emergency Hospital, Timisoara, Romania; 3Department of Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 4Department of Public Health, Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, Bucuresti, RomaniaCorrespondence: Mirela FrandesDepartment of Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 2 Eftimie Murgu, Timisoara 300041, RomaniaTel +40 731117020Fax +40 256462856Email mirela.frandes@umft.roBackground: In developing countries, cancer incidence has progressively increased, becoming the second cause of mortality after cardiovascular diseases. Type 2 diabetes mellitus (T2DM) is associated with an increased risk of malignant neoplastic disorders, especially pancreatic cancer, colorectal cancer, and breast cancer.Aim: The main aim of our study was to establish the prevalence of malignant neoplastic disorders in patients previously diagnosed with T2DM. Also, we have investigated the association between the components of the metabolic syndrome (MetS) and the different types of diagnosed malignant neoplasms.Methods: We performed a retrospective, population-based cohort study of 1,027 patients with T2DM from the Center for Diabetes Treatment of the “Pius Brînzeu” Emergency Hospital in Timisoara, Romania. The patients were followed up every three or six months, depending on their antidiabetic treatment. The patients who developed malignant neoplasms were registered and referred to oncology centers. The potential risk factors for malignancies in patients with T2DM were evaluated using logistic regression adjusting for possible confounders.Results: The prevalence of malignant neoplastic disorders in our study group was 7.1%; more precisely, we found 2.2% colon neoplasm, 2.9% mammary neoplasm, 0.7% lymphomas, 0.6% pulmonary neoplasm, 0.3% pancreatic neoplasm, and 0.4% prostate neoplasm. The presence of malignant neoplastic disorders was associated in our cohort of patients with T2DM with higher cholesterol (237.71± 47.82 vs 202.52± 52.16 mg/dL; p=0.005) and triglycerides levels (215.91± 52.41 vs 180.75± 54.32 mg/dL; p< 0.001), as well as higher body mass index (33.37± 3.87 vs 28.42± 3.56 kg/m2; p< 0.001) and abdominal circumference (110.11± 14.48 vs 98.12± 15.73 cm; p< 0.001). Also, we found that insulin-based treatment was an independent risk factor, the patients presenting ten times higher odds of developing malignant neoplastic disorders.Conclusion: The prevalence of malignant neoplastic disorders in our study group was 7.1%. Also, the prevalence of malignant neoplastic disorders was higher in patients with T2DM and MetS as compared to the general population of T2DM patients.Keywords: malignant neoplastic disorders, type 2 diabetes mellitus, hyperinsulinemia, metabolic syndrome, insulin resistanceAlbai OFrandes MTimar BPaun DLRoman DTimar RDove Medical Pressarticlemalignant neoplastic disorderstype 2 diabetes mellitushyperinsulinemiametabolic syndromeinsulin resistanceSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 1317-1326 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	malignant neoplastic disorders type 2 diabetes mellitus hyperinsulinemia metabolic syndrome insulin resistance Specialties of internal medicine RC581-951
spellingShingle	malignant neoplastic disorders type 2 diabetes mellitus hyperinsulinemia metabolic syndrome insulin resistance Specialties of internal medicine RC581-951 Albai O Frandes M Timar B Paun DL Roman D Timar R Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome
description	Oana Albai,1,2 Mirela Frandes,3 Bogdan Timar,2,3 Diana-Loreta Paun,4 Deiana Roman,1 Romulus Timar1,2 1Second Department of Internal Medicine, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 2Department of Diabetes and Metabolic Diseases, “Pius Brinzeu” Emergency Hospital, Timisoara, Romania; 3Department of Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania; 4Department of Public Health, Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, Bucuresti, RomaniaCorrespondence: Mirela FrandesDepartment of Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 2 Eftimie Murgu, Timisoara 300041, RomaniaTel +40 731117020Fax +40 256462856Email mirela.frandes@umft.roBackground: In developing countries, cancer incidence has progressively increased, becoming the second cause of mortality after cardiovascular diseases. Type 2 diabetes mellitus (T2DM) is associated with an increased risk of malignant neoplastic disorders, especially pancreatic cancer, colorectal cancer, and breast cancer.Aim: The main aim of our study was to establish the prevalence of malignant neoplastic disorders in patients previously diagnosed with T2DM. Also, we have investigated the association between the components of the metabolic syndrome (MetS) and the different types of diagnosed malignant neoplasms.Methods: We performed a retrospective, population-based cohort study of 1,027 patients with T2DM from the Center for Diabetes Treatment of the “Pius Brînzeu” Emergency Hospital in Timisoara, Romania. The patients were followed up every three or six months, depending on their antidiabetic treatment. The patients who developed malignant neoplasms were registered and referred to oncology centers. The potential risk factors for malignancies in patients with T2DM were evaluated using logistic regression adjusting for possible confounders.Results: The prevalence of malignant neoplastic disorders in our study group was 7.1%; more precisely, we found 2.2% colon neoplasm, 2.9% mammary neoplasm, 0.7% lymphomas, 0.6% pulmonary neoplasm, 0.3% pancreatic neoplasm, and 0.4% prostate neoplasm. The presence of malignant neoplastic disorders was associated in our cohort of patients with T2DM with higher cholesterol (237.71± 47.82 vs 202.52± 52.16 mg/dL; p=0.005) and triglycerides levels (215.91± 52.41 vs 180.75± 54.32 mg/dL; p< 0.001), as well as higher body mass index (33.37± 3.87 vs 28.42± 3.56 kg/m2; p< 0.001) and abdominal circumference (110.11± 14.48 vs 98.12± 15.73 cm; p< 0.001). Also, we found that insulin-based treatment was an independent risk factor, the patients presenting ten times higher odds of developing malignant neoplastic disorders.Conclusion: The prevalence of malignant neoplastic disorders in our study group was 7.1%. Also, the prevalence of malignant neoplastic disorders was higher in patients with T2DM and MetS as compared to the general population of T2DM patients.Keywords: malignant neoplastic disorders, type 2 diabetes mellitus, hyperinsulinemia, metabolic syndrome, insulin resistance
format	article
author	Albai O Frandes M Timar B Paun DL Roman D Timar R
author_facet	Albai O Frandes M Timar B Paun DL Roman D Timar R
author_sort	Albai O
title	Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome
title_short	Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome
title_full	Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome
title_fullStr	Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome
title_full_unstemmed	Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome
title_sort	long‐term risk of malignant neoplastic disorders in type 2 diabetes mellitus patients with metabolic syndrome
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/9c28a5d6427d418f9b51493c810b66ab
work_keys_str_mv	AT albaio longtermriskofmalignantneoplasticdisordersintype2diabetesmellituspatientswithmetabolicsyndrome AT frandesm longtermriskofmalignantneoplasticdisordersintype2diabetesmellituspatientswithmetabolicsyndrome AT timarb longtermriskofmalignantneoplasticdisordersintype2diabetesmellituspatientswithmetabolicsyndrome AT paundl longtermriskofmalignantneoplasticdisordersintype2diabetesmellituspatientswithmetabolicsyndrome AT romand longtermriskofmalignantneoplasticdisordersintype2diabetesmellituspatientswithmetabolicsyndrome AT timarr longtermriskofmalignantneoplasticdisordersintype2diabetesmellituspatientswithmetabolicsyndrome
_version_	1718393519875293184

Long‐term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome

Ejemplares similares